title: [Treatment of malignant tumors by interleukin 2 and LAK cells].
abstract: Lymphokine-activated killer (LAK) cells are cells able to lyse fresh tumor cells. In vivo treatment using LAK cells and interleukin 2 is highly toxic because of increased capillary permeability. International discussion is underway on this promising or too toxic therapy. However, such treatment opens a new way for ex vivo manipulation of cells.
authors.affiliation: Service d'Hématologie, Hôpital Saint-Louis, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Degos
mesh_terms: D002199:Capillary Permeability / Q000187:drug effects; D006801:Humans; D007116:Immunization, Passive / Q000009:adverse effects; D007376:Interleukin-2 / Q000009:adverse effects / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000187:drug effects / Q000276:immunology*; D008222:Lymphokines / Q000494:pharmacology; D009369:Neoplasms / Q000628:therapy*
chemical_list: D007376:Interleukin-2; D008222:Lymphokines
vernacular_title: Traitement des tumeurs malignes par interleukine 2 et cellules cellules LAK.